Sirana Pharma and Pfizer to investigate novel treatment for a rare bone disease

Sirana Pharma, a biotechnology company focusing on the development of treatments for unmet medical needs in muscle and bone diseases, has entered into a collaborative research agreement with Pfizer to investigate the potential identification and validation of a novel treatment concept for a rare bone disease.

The collaboration will utilize Sirana’s proprietary microRNA (miRNA)-targeting approach, which targets substantial regenerative recovery of diseased muscle and bone tissue.

“Combining Sirana’s novel miRNA-targeting approach, and the long-standing experience in
musculoskeletal disorders and disease mechanisms of its founders, with the expertise and
competencies of Pfizer will allow Sirana to expeditiously evaluate its drug candidates for the
treatment of this rare disease and to identify potential candidates for further development,” said Michael Kring, CEO of Sirana Pharma GmbH.

“At Pfizer, we are committed to advancing promising, emerging research – both through our
internal capabilities and through collaborations with companies like Sirana – with the goal of bringing potentially life-changing medicines to patients around the world,” said Seng H. Cheng, Ph.D., senior vice president and chief scientific officer, Pfizer Rare Disease.

“We look forward to working together with the Sirana team to further explore this new and innovative investigational approach, utilizing miRNA-targeting for the potential treatment of rare bone diseases.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news